Replies to post #145503 on Biotech Values

[DewDiligence]

My view exactly. For a paltry $1/sh, couldn’t they have worked it out without the poison pill, the aborted tender offer, and all the nasty press releases?

[DewDiligence]

GSK-HGSI deal is official at $14.25/sh (not $14, as previously reported):

http://finance.yahoo.com/news/gsk-acquire-human-genome-sciences-131500304.html

…the companies have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The transaction values HGS at approximately US$3.6 billion on an equity basis, or approximately US$3 billion net of cash and debt, and represents a premium of 99% to the HGS closing price of US$7.17 per share on 18 April 2012, the last day of trading before HGS publicly disclosed GSK’s initial private offer. The Boards of Directors of both companies have approved the transaction.